patent.fyi
Applications  /  US 2026/0355344
United States Patent Application Publication

US 2026/0355344 A1

Published
Nov 12, 2026
Filed
May 27, 2024
Earliest date on the face
May 26, 2023
Classification
A61K 47/6901
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Affinity binding to the membrane

What ifWhat if reversible affinity binding holds the compound at the inner membrane surface?
Claim language“covalently attached”

A membrane protein presents a lumen-facing nickel chelate that binds a polyhistidine tag on a model enzyme. A protease cleaves the peptide between the tag and the enzyme, releasing the enzyme while the tag remains bound.

1.1Cargo on the outer surface

What ifWhat if the compound attaches to the outer membrane surface?
Claim language“internal surface of the EV membrane”

A transmembrane anchor presents a peptide linker and a conjugated model peptide on the exterior of the vesicle. A soluble protease cuts the exposed linker and releases the model peptide into the surrounding fluid.

1.1Acid triggered cargo release

What ifWhat if an acid-sensitive hydrazone controls release from the membrane?
Claim language“endoprotease-cleavable linker”

A hydrazide on a lumen-facing membrane anchor reacts with the ketone group of a model drug to form a hydrazone. Acidification of the vesicle lumen accelerates hydrolysis and regenerates the drug's ketone group.

1.1Light triggered cargo release

What ifWhat if a light-sensitive chemical group controls release from the membrane?
Claim language“endoprotease-cleavable linker”

An ortho-nitrobenzyl carbamate joins a lumen-facing lipid anchor to the amino group of a model compound. Illumination at 365 nm cleaves the carbamate and regenerates the free amino group.

1.1Soluble cargo in the lumen

What ifWhat if the compound remains dissolved in the vesicle lumen?
Claim language“covalently attached to the internal surface”

Transient permeabilization admits a water-soluble model drug, and membrane resealing traps it in the aqueous lumen. Size-exclusion chromatography removes external drug, and membrane fusion with a recipient cell membrane releases the luminal drug into the cytosol.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Reference particles for fluorescence instrument checks

Extracellular vesicles carry a fluorophore and quencher on opposite sides of an endoprotease-cleavable peptide that is covalently tethered to the inner membrane surface. A plate reader records the baseline fluorescence of intact particles in a cell-free well. Detergent opens the vesicles, and an added endoprotease cleaves the peptide and separates the fluorophore from the quencher. The fluorescence change provides a reference signal for checking reader response.

Component substitution

Integral membrane protein as the tether

A single-pass transmembrane protein anchors a reporter to the inner surface of the extracellular vesicle. The protein's cytosolic tail in the producer cell forms a continuous polypeptide with an endoprotease-cleavable peptide and a fluorescent reporter. Vesicle budding places the tail, peptide, and reporter in the lumen. In a cell-free assay, membrane solubilization exposes the peptide to an added endoprotease, which releases the reporter from the anchor.

Parameter or scale variation

Two particle size fractions for release assays

An extracellular vesicle preparation contains an internally tethered fluorescent reporter joined to its anchor by an endoprotease-cleavable linker. Asymmetric flow field-flow fractionation separates the preparation into fractions with measured hydrodynamic diameters of 70–100 and 120–160 nanometers. Each fraction supplies 100 microliters per well at the same particle concentration. After detergent treatment and endoprotease addition, the plate reader records fluorescence every 30 seconds for 10 minutes.

Combination with existing systems

Two stage microfluidic reporter release

A continuous-flow microfluidic chip receives extracellular vesicles with a reporter covalently tethered to the inner membrane through an endoprotease-cleavable linker. The first mixing junction combines the vesicle stream with a mild detergent to expose the linker. A second junction introduces detergent-compatible endoprotease, and a downstream observation channel measures fluorescence from the cleaved reporter. Pump flow rates and the channel volume between the second junction and the detector set the reaction time.

Chromatographic separation of released enzyme reporter

Extracellular vesicles carry a phosphatase reporter covalently joined to an inward-facing membrane protein through an endoprotease-cleavable linker. A detergent that preserves phosphatase activity solubilizes the membrane, and an added endoprotease releases the phosphatase. An affinity column captures a peptide tag on the anchor side of the linker, and the released phosphatase passes through the column. A chromogenic phosphatase substrate measures reporter activity in the collected fraction.

Automated or data-driven variant

Automated measurement of reporter release kinetics

A liquid handler dispenses extracellular vesicles carrying an internally tethered, quenched fluorescent reporter into a microplate. After detergent opens the vesicles, the handler adds endoprotease to the reaction wells and buffer to matched control wells. Software uses the dispensing timestamp to align each fluorescence trace and subtracts the control signal. It fits the initial linear portion of the corrected trace and reports the release rate for each well.

Specific version of a part

Peptide tether on a tetraspanin

A tetraspanin carries a model enzyme on its cytosolic C terminus through a peptide spacer containing a protease recognition sequence. Vesicle budding places the fusion inside the vesicle, where a matching endoprotease cleaves the spacer and frees the enzyme from the membrane.

Lipid tether with peptide cleavage

A phosphatidylethanolamine headgroup forms an amide bond to one end of a protease-cleavable peptide, and the other end carries a covalently attached model peptide cargo. Budding from the membrane places conjugates from its cytosolic leaflet on the vesicle's inner surface, where cleavage within the tether separates the cargo from the lipid anchor.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2007/0037891 A1
Published
Feb 15, 2007
Filed
Apr 14, 2006
Class
A61K 47/00
Document BUS 2021/0030850 A1
Published
Feb 4, 2021
Filed
Apr 10, 2019
Class
A61K 38/465
Claim 1
Document A
Document B
1.1a biologically active compound covalently attached to the internal surface of the EV membrane via at least one endoprotease-cleavable linker.
No. 6,770,725 describes the covalent attachment of bioactive compounds to polymers with oligofluoro end groups. This approach was used to position biologically active agents at the surface of devices, to improve the biocompatibility of the device surface by modifying the surface with oligofluoro end groups, and to enhance the thermodynamic compatibility of the polymer-bioactive compound conjugate with the base polymer.
A · US 2007/0037891 A1 · ¶ 8
In some embodiments of the disclosed extracellular vesicles, the fusion protein comprises the RNA-binding domain fused to the C-terminus of one of SEQ ID NOs:23, 24, 25, and 27, which comprise a portion of the C-termini of LAMP-2a, LAMP-2b, LAMP-2c, and LAMP-1, respectively). The fusion protein may include the cytoplasmic domain of a LAMP and optionally may include additional amino acid sequences (e.g., at least a portion of the transmembrane domain and/or at least a portion of the luminal domain).
B · US 2021/0030850 A1 · ¶ 38

An empty cell means only that no passage was reproduced there.

Statements in these documents
Mixing lowers the entropy and this can result in phase separation throughout the bulk polymer, compromising the physical/mechanical properties of the polymeric coating.
A · US 2007/0037891 A1 · ¶ 7
The polymers described allow the base polymer to retain its bulk properties.
A · US 2007/0037891 A1 · ¶ 8
In particular, the described technology provides a robust method for display of targeting proteins on the surface of EVs via the expression of engineered proteins that localize to EVs and exhibit external affinity domains.
B · US 2021/0030850 A1 · ¶ 5
As such, the disclosed technology may be used for engineering targeted EVs which could be applied to a wide variety of cell types and diseases.
B · US 2021/0030850 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355344 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355344/, SHA-256 ff085e81853c63a2b9b5dec06e1f655e5a7138277cad79828c0e32ebb4657a62
First published
Permanent addresshttps://patent.fyi/US20260355344/
Content fingerprint (SHA-256)ff085e81853c63a2b9b5dec06e1f655e5a7138277cad79828c0e32ebb4657a62
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi